NDAORALTABLETPriority Review
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
PH 2 Pemigatinib in SDH-deficient GIST
Started Jun 2026
24 enrolled
SDH Gene MutationGastrointestinal Stromal Tumor
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Started Jan 2026
38 enrolled
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Started Oct 2025
27 enrolled
Relapsed or Refractory B-cell Non-Hodgkin LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Started Aug 2025
40 enrolled
Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+2 more
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Started Mar 2025
40 enrolled
Solid Tumor, Miscellaneous
Loss of Exclusivity
LOE Date
Aug 30, 2040
176 months away
Patent Expiry
Aug 30, 2040
Exclusivity Expiry
Aug 26, 2029
Company
Incyte
DE - Wilmington